{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:10:48Z","timestamp":1756383048658},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract and is characterized by KIT mutations. Patientsresistant to 1st-line imatinib therapy are usually given sunitinib assecond-line treatment, which provides a median progression-free survival of 8 to 12 months. We report the 1st case of metastatic jejunum GIST with a KIT exon 11 deletion that showed complete response (CR) to sunitinib for more than 3 years.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 34-year-old man with advanced jejunum GIST was surgically treated upon initial diagnosis, and was histologically found to carry a high recurrence risk. Genetic testing revealed a KIT exon 11 deletion, and adjuvant therapy with imatinib was administered. The imatinib dose was escalated following recurrence in the abdomen, but the mass continued to grow.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>He was diagnosed with abdominal recurrence of GIST based on his medical history and histopathological results.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Intervention:<\/jats:title>\n            <jats:p>Second-line sunitinib therapy was given.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The mass disappeared, and CR was seen following 7 months of sunitinib therapy; this CR was sustained for more than 45 months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>In cases of metastatic jejunum GIST with a KIT exon 11 deletion, sunitinib as second-line therapy can be used to achieve CR for more than 3 years.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000014060","type":"journal-article","created":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T03:06:45Z","timestamp":1547694405000},"page":"e14060","source":"Crossref","is-referenced-by-count":2,"title":["Complete response to sunitinib for more than three years in a patient with a jejunum gastrointestinal stromal tumor"],"prefix":"10.1097","volume":"98","author":[{"given":"Yanli","family":"Nie","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The Hubei Cancer Hospital, Huazhong University of Science and Technology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjia","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Hubei Cancer Hospital, Huazhong University of Science and Technology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihua","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The Hubei Cancer Hospital, Huazhong University of Science and Technology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengwei","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgical Oncology, The Hubei Cancer Hospital, Huazhong University of Science and Technology, Wuhan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230914","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2559.2005.02291.x","article-title":"Gastrointestinal stromal tumours: an update","volume":"48","author":"Rubin","year":"2006","journal-title":"Histopathology"},{"key":"R2-20230914","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/cncr.29220","article-title":"Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib","volume":"121","author":"Reichardt","year":"2015","journal-title":"Cancer"},{"key":"R3-20230914","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.1200\/JCO.2005.11.601","article-title":"Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study","volume":"23","author":"Van Glabbeke","year":"2005","journal-title":"J Clin Oncol"},{"key":"R4-20230914","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"key":"R5-20230914","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.ejca.2009.02.011","article-title":"Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure","volume":"45","author":"George","year":"2009","journal-title":"Eur J Cancer"},{"key":"R6-20230914","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/00000478-200604000-00008","article-title":"Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up","volume":"30","author":"Miettinen","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"R7-20230914","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1200\/JCO.2004.05.140","article-title":"Biology of gastrointestinal stromal tumors","volume":"22","author":"Corless","year":"2004","journal-title":"J Clin Oncol"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S0046-8177(03)00407-6","article-title":"KIT 1530ins6 mutation defines a subset of predominantly malignant gastrointestinal stromal tumors of intestinal origin","volume":"34","author":"Lasota","year":"2003","journal-title":"Human Pathol"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1200\/JCO.2003.04.190","article-title":"Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor","volume":"21","author":"Heinrich","year":"2003","journal-title":"J Clin Oncol"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1073\/pnas.1009199108","article-title":"Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations","volume":"108","author":"Janeway","year":"2011","journal-title":"Proc Nat Acad Sci U S A"},{"key":"R11-20230914","doi-asserted-by":"crossref","first-page":"5360","DOI":"10.1200\/JCO.2008.17.4284","article-title":"Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group","volume":"26","author":"Heinrich","year":"2008","journal-title":"J Clin Oncol"},{"key":"R12-20230914","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/01.pas.0000146010.92933.de","article-title":"Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up","volume":"29","author":"Miettinen","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"R13-20230914","first-page":"1361","article-title":"Deletion of the KIT gene is associated with liver metastasis and poor prognosis in patients with gastrointestinal stromal tumor in the stomach","volume":"28","author":"Cho","year":"2006","journal-title":"Int J Oncol"},{"key":"R14-20230914","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00384-011-1353-y","article-title":"Gastrointestinal stromal tumors","volume":"27","author":"Beham","year":"2012","journal-title":"Int J Colorectal Dis"},{"key":"R15-20230914","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ijsu.2012.05.007","article-title":"Current management of gastrointestinal stromal tumors\u2013a comprehensive review","volume":"10","author":"Lai","year":"2012","journal-title":"Int J Surg"},{"key":"R16-20230914","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00000658-200001000-00008","article-title":"Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival","volume":"231","author":"DeMatteo","year":"2000","journal-title":"Ann Surg"},{"key":"R17-20230914","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12885-016-2051-5","article-title":"Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial","volume":"16","author":"Reichardt","year":"2016","journal-title":"BMC cancer"},{"key":"R18-20230914","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1200\/JCO.2007.15.7461","article-title":"Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor","volume":"26","author":"Heinrich","year":"2008","journal-title":"J Clin Oncol"},{"key":"R19-20230914","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.2217\/fon-2017-0252","article-title":"Clinical benefit of sunitinib in gastrointestinal stromal tumors with different exon 11 mutation genotypes","volume":"13","author":"Dong","year":"2017","journal-title":"Future Oncol"},{"key":"R20-20230914","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.3748\/wjg.v17.i16.2113","article-title":"Sunitinib for Taiwanese patients with gastrointestinal stromal tumor after imatinib treatment failure or intolerance","volume":"17","author":"Chen","year":"2011","journal-title":"World J Gastroenterol"},{"key":"R21-20230914","first-page":"221","article-title":"[Efficacy and safety of sunitinib on patients with imatinib-resistant gastrointestinal stromal tumor]","volume":"16","author":"Liu","year":"2013","journal-title":"Zhonghua wei chang wai ke za zhi\u200a=\u200aChinese J Gastroint Surg"},{"key":"R22-20230914","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3892\/mco.2017.1268","article-title":"Complete response to second-line chemotherapy with sunitinib of a gastrointestinal stromal tumor: a case report","volume":"7","author":"Shirakawa","year":"2017","journal-title":"Mol Clin Oncol"},{"issue":"(Suppl 2)","key":"R23-20230914","first-page":"S1","article-title":"NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors","volume":"8","author":"Demetri","year":"2010","journal-title":"J Nat Compreh Cancer Network: JNCCN"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201901180-00031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T19:30:33Z","timestamp":1694719833000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201901180-00031"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000014060","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}